About
Technology
Issues
FAQ
Links
Official Page
Impact of Dose Intensity on Pathologic Complete Response Rate in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab and Pertuzumab (TCHP)
site/software ©
exaly
; All materials licenced under
CC by-SA
.